June 14, 2013
A number of sodium glucose co-transporter-2 (SGLT-2) inhibitors, which offer a new option for the treatment of diabetes, are nearing approval. The companies involved are competing fiercely for their products to be first-in-class, but Astellas Pharma is in the vanguard,...read more